Financial Performance - For the fiscal year ending December 31, 2022, the company reported a revenue of RMB 3,744.95 million, an increase of 309.83% compared to the previous year[2] - The EBITDA for the same period was RMB 698.43 million, reflecting a growth of 502.63% year-over-year[2] - The net profit attributable to equity holders of the company was RMB 76.60 million, a significant recovery from a loss of RMB 587.65 million in the previous year[2] - Basic earnings per share for the fiscal year was RMB 0.09, compared to a loss per share of RMB 0.67 in the prior year[4] - The gross profit margin improved significantly, with gross profit reported at RMB 2,846.07 million, up from RMB 483.70 million the previous year[4] - The company reported a significant reduction in operating losses, with operating profit of RMB 321.07 million compared to a loss of RMB 423.38 million in the previous year[4] - The company reported a net profit of RMB 76,603 thousand for the year 2022, recovering from a loss of RMB (587,649) thousand in 2021[8] - The group recorded a pre-tax profit of RMB 39.42 million for the year ended December 31, 2022, an increase of RMB 706.60 million compared to a pre-tax loss of RMB 667.18 million for the previous year[70] - The net profit for the group was RMB 49.24 million for the year ended December 31, 2022, an increase of 108.38% from a net loss of RMB 587.72 million for the year ended December 31, 2021[73] Revenue Sources - The total revenue for the year 2022 was RMB 3,744,952,000, a significant increase from RMB 913,788,000 in 2021, representing a growth of approximately 309%[15] - The sales of antiviral drugs reached RMB 3,116,059,000 in 2022, compared to RMB 559,973,000 in 2021, indicating a growth of about 455%[15] - The core product, Kewai (Phosphate Oseltamivir), generated sales of RMB 3,092.71 million, representing a 457.66% increase year-on-year[53] - Kewai (Phosphate Oseltamivir) accounted for 82.58% of total revenue, while other products contributed significantly less, with the next highest being Ertongshu (Bromfenac Tablets) at 2.63%[53] - The sales of Kewai (Phosphate Oseltamivir) granules reached RMB 2,585.15 million, making up 69.03% of total revenue[59] - The sales of Kewai (Phosphate Oseltamivir) capsules were RMB 507.55 million, accounting for 13.55% of total revenue[59] Expenses and Costs - Total expenses for the group reached RMB 1,962.31 million for the year ended December 31, 2022, an increase of 58.67% from RMB 1,236.73 million for the year ended December 31, 2021[67] - Distribution costs increased by 133.21% to RMB 1,216.59 million, primarily due to increased marketing costs associated with higher product sales volume[68] - R&D expenses totaled RMB 199.24 million, accounting for 5.32% of revenue, a decrease of 19.08% year-on-year[69] - The sales cost for the year was RMB 898.88 million, a 109.00% increase from RMB 430.09 million in the previous year, mainly due to increased sales volume of Kewai[64] Assets and Liabilities - Total assets as of December 31, 2022, were RMB 6,949.02 million, down from RMB 9,303.52 million the previous year[6] - The company’s cash and cash equivalents amounted to RMB 923.54 million, compared to RMB 1,131.12 million in the previous year[6] - The company’s total liabilities decreased to RMB 879,018 thousand from RMB 879,018 thousand, reflecting a stable financial position[7] - The company has a total of RMB 1,718,222,000 in financial liabilities measured at amortized cost as of 2022, up from RMB 911,680,000 in 2021[44] Investments and Capital Expenditures - The company invested RMB 290,000,000 in a trust investment plan as part of its financial strategy[34] - Capital expenditures for the year included RMB 853.06 million for construction of facilities, purchase of office equipment, and acquisition of drug production and marketing rights[81] - The company has ongoing applications for property ownership certificates valued at RMB 544,900,000 as of December 31, 2022, up from RMB 415,843,000 in 2021, representing an increase of approximately 30.9%[26] Research and Development - The company will continue to increase R&D investment, focusing on drug development in areas such as anti-infection, endocrine, and metabolic diseases, aiming for clinical application[88] - The company has established a comprehensive R&D system for insulin products, covering both second and third-generation insulin[55] - The company’s R&D investment in the field of diabetes treatment amounted to RMB 39,887.19 thousand for the drug Jiao Guo An Suan Rong Ge Lian Jing, representing 1.07% of revenue[58] Corporate Governance and Shareholder Relations - The company did not declare a final dividend for the fiscal year ending December 31, 2022[4] - The company did not declare or pay dividends for the years ending December 31, 2021, and December 31, 2022[50] - The company has received eight waiver letters from bondholders, allowing them to waive their rights to early redemption of convertible bonds until January 1, 2023[48] Employee and Management - The group employed 4,167 individuals as of December 31, 2022, with total employee costs approximately RMB 612.18 million[83] - The employee age distribution showed that 75.59% were aged between 31 and 50 years, while 21.53% were 30 years or younger[84] - The group’s compensation policy aims to motivate and retain talent, regularly reviewing employee compensation based on industry standards and performance[86] Future Outlook - The company anticipates steady growth in the innovative drug market, supported by favorable government policies and an expanding national medical insurance drug list[51] - The company plans to enhance its product portfolio by continuously launching new products to strengthen market competitiveness[88] - The company aims to improve its scientific and sustainable marketing strategies, promoting core products in tiered hospitals and grassroots medical markets[88]
东阳光长江药业(01558) - 2022 - 年度业绩